Cargando…
Phase II Study of Dehydroepiandrosterone in Androgen Receptor‐Positive Metastatic Breast Cancer
LESSONS LEARNED. The androgen receptor (AR) is present in most breast cancers (BC), but its exploitation as a therapeutic target has been limited. This study explored the activity of dehydroepiandrosterone (DHEA), a precursor being transformed into androgens within BC cells, in combination with an a...
Autores principales: | Pietri, Elisabetta, Massa, Ilaria, Bravaccini, Sara, Ravaioli, Sara, Tumedei, Maria Maddalena, Petracci, Elisabetta, Donati, Caterina, Schirone, Alessio, Piacentini, Federico, Gianni, Lorenzo, Nicolini, Mario, Campadelli, Enrico, Gennari, Alessandra, Saba, Alessandro, Campi, Beatrice, Valmorri, Linda, Andreis, Daniele, Fabbri, Francesco, Amadori, Dino, Rocca, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6656524/ https://www.ncbi.nlm.nih.gov/pubmed/30591548 http://dx.doi.org/10.1634/theoncologist.2018-0243 |
Ejemplares similares
-
Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?
por: Bronte, Giuseppe, et al.
Publicado: (2018) -
Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
por: Bronte, Giuseppe, et al.
Publicado: (2018) -
Cell-free DNA detected by “liquid biopsy” as a potential prognostic biomarker in early breast cancer
por: Maltoni, Roberta, et al.
Publicado: (2017) -
Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ
por: Farolfi, Alberto, et al.
Publicado: (2020) -
The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects
por: Bravaccini, Sara, et al.
Publicado: (2021)